SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al....
Main Authors: | Mei Qiu, Xu-Bin Wei, Wei Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-12-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.791311/full |
Similar Items
-
Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
by: Lixin Du, et al.
Published: (2022-08-01) -
Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
by: Lixin Du, et al.
Published: (2022-09-01) -
GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
by: Alessio Mazzieri, et al.
Published: (2023-11-01) -
GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
by: Hongle Yan, et al.
Published: (2022-07-01) -
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
by: Angelica Cersosimo, et al.
Published: (2024-03-01)